1. Home
  2. XYZ vs TAK Comparison

XYZ vs TAK Comparison

Compare XYZ & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XYZ
  • TAK
  • Stock Information
  • Founded
  • XYZ 2009
  • TAK 1781
  • Country
  • XYZ United States
  • TAK Japan
  • Employees
  • XYZ N/A
  • TAK N/A
  • Industry
  • XYZ
  • TAK Biotechnology: Pharmaceutical Preparations
  • Sector
  • XYZ
  • TAK Health Care
  • Exchange
  • XYZ NYSE
  • TAK Nasdaq
  • Market Cap
  • XYZ 52.4B
  • TAK 42.2B
  • IPO Year
  • XYZ 2015
  • TAK N/A
  • Fundamental
  • Price
  • XYZ $68.32
  • TAK $14.07
  • Analyst Decision
  • XYZ Buy
  • TAK
  • Analyst Count
  • XYZ 34
  • TAK 0
  • Target Price
  • XYZ $95.63
  • TAK N/A
  • AVG Volume (30 Days)
  • XYZ 7.2M
  • TAK 1.8M
  • Earning Date
  • XYZ 02-20-2025
  • TAK 01-30-2025
  • Dividend Yield
  • XYZ N/A
  • TAK 3.63%
  • EPS Growth
  • XYZ 28312.98
  • TAK 15.39
  • EPS
  • XYZ 4.56
  • TAK 0.83
  • Revenue
  • XYZ $24,121,053,000.00
  • TAK $29,124,927,177.00
  • Revenue This Year
  • XYZ $13.81
  • TAK $7.80
  • Revenue Next Year
  • XYZ $11.52
  • TAK $0.36
  • P/E Ratio
  • XYZ $14.99
  • TAK $33.80
  • Revenue Growth
  • XYZ 10.06
  • TAK 9.83
  • 52 Week Low
  • XYZ $55.00
  • TAK $12.58
  • 52 Week High
  • XYZ $99.26
  • TAK $15.08
  • Technical
  • Relative Strength Index (RSI)
  • XYZ N/A
  • TAK 64.16
  • Support Level
  • XYZ N/A
  • TAK $13.66
  • Resistance Level
  • XYZ N/A
  • TAK $13.97
  • Average True Range (ATR)
  • XYZ 0.00
  • TAK 0.13
  • MACD
  • XYZ 0.00
  • TAK 0.06
  • Stochastic Oscillator
  • XYZ 0.00
  • TAK 96.15

About XYZ BLOCK INC

Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.

About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Share on Social Networks: